Close Menu

NEW YORK – Oncocyte said Thursday that it has agreed to enter a licensing and collaboration agreement with Chronix Biomedical.

Under the agreement, Oncocyte is licensing Chronix's patented technology for blood-based copy number instability testing. In turn, Chronix will use its laboratory network in Germany to accelerate the EU market commercial launch of Oncocyte's DetermaRx.

Financial terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.